BRPI1014139A2 - sistema de liberação de fármacos compreendendo polioxazolina e um agente biotivo. - Google Patents
sistema de liberação de fármacos compreendendo polioxazolina e um agente biotivo.Info
- Publication number
- BRPI1014139A2 BRPI1014139A2 BRPI1014139A BRPI1014139A BRPI1014139A2 BR PI1014139 A2 BRPI1014139 A2 BR PI1014139A2 BR PI1014139 A BRPI1014139 A BR PI1014139A BR PI1014139 A BRPI1014139 A BR PI1014139A BR PI1014139 A2 BRPI1014139 A2 BR PI1014139A2
- Authority
- BR
- Brazil
- Prior art keywords
- biotive
- polyoxazoline
- agent
- delivery system
- drug delivery
- Prior art date
Links
- 239000003795 chemical substances by application Substances 0.000 title 1
- 238000012377 drug delivery Methods 0.000 title 1
- 229920000765 poly(2-oxazolines) Polymers 0.000 title 1
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/0012—Galenical forms characterised by the site of application
- A61K9/0053—Mouth and digestive tract, i.e. intraoral and peroral administration
- A61K9/0056—Mouth soluble or dispersible forms; Suckable, eatable, chewable coherent forms; Forms rapidly disintegrating in the mouth; Lozenges; Lollipops; Bite capsules; Baked products; Baits or other oral forms for animals
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/0012—Galenical forms characterised by the site of application
- A61K9/0053—Mouth and digestive tract, i.e. intraoral and peroral administration
- A61K9/006—Oral mucosa, e.g. mucoadhesive forms, sublingual droplets; Buccal patches or films; Buccal sprays
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/14—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles
- A61K9/16—Agglomerates; Granulates; Microbeadlets ; Microspheres; Pellets; Solid products obtained by spray drying, spray freeze drying, spray congealing,(multiple) emulsion solvent evaporation or extraction
- A61K9/1605—Excipients; Inactive ingredients
- A61K9/1629—Organic macromolecular compounds
- A61K9/1641—Organic macromolecular compounds obtained otherwise than by reactions only involving carbon-to-carbon unsaturated bonds, e.g. polyethylene glycol, poloxamers
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/14—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles
- A61K9/16—Agglomerates; Granulates; Microbeadlets ; Microspheres; Pellets; Solid products obtained by spray drying, spray freeze drying, spray congealing,(multiple) emulsion solvent evaporation or extraction
- A61K9/1682—Processes
- A61K9/1694—Processes resulting in granules or microspheres of the matrix type containing more than 5% of excipient
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/20—Pills, tablets, discs, rods
- A61K9/2004—Excipients; Inactive ingredients
- A61K9/2022—Organic macromolecular compounds
- A61K9/2031—Organic macromolecular compounds obtained otherwise than by reactions only involving carbon-to-carbon unsaturated bonds, e.g. polyethylene glycol, polyethylene oxide, poloxamers
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/48—Preparations in capsules, e.g. of gelatin, of chocolate
- A61K9/4816—Wall or shell material
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/70—Web, sheet or filament bases ; Films; Fibres of the matrix type containing drug
- A61K9/7007—Drug-containing films, membranes or sheets
Landscapes
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Veterinary Medicine (AREA)
- Public Health (AREA)
- Animal Behavior & Ethology (AREA)
- General Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Medicinal Chemistry (AREA)
- Pharmacology & Pharmacy (AREA)
- Epidemiology (AREA)
- Engineering & Computer Science (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Nutrition Science (AREA)
- Physiology (AREA)
- Zoology (AREA)
- Medicinal Preparation (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
Applications Claiming Priority (2)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| EP09164023 | 2009-06-29 | ||
| PCT/NL2010/050403 WO2011002285A1 (en) | 2009-06-29 | 2010-06-28 | Drug delivery system comprising polyoxazoline and a bioactive agent |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| BRPI1014139A2 true BRPI1014139A2 (pt) | 2016-04-26 |
Family
ID=41381741
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| BRPI1014139A BRPI1014139A2 (pt) | 2009-06-29 | 2010-06-28 | sistema de liberação de fármacos compreendendo polioxazolina e um agente biotivo. |
Country Status (10)
| Country | Link |
|---|---|
| US (1) | US8642080B2 (pt) |
| EP (1) | EP2448567B1 (pt) |
| JP (1) | JP5666574B2 (pt) |
| KR (1) | KR101701544B1 (pt) |
| CN (1) | CN102481264B (pt) |
| BR (1) | BRPI1014139A2 (pt) |
| CA (1) | CA2766482C (pt) |
| ES (1) | ES2409055T3 (pt) |
| MX (1) | MX2012000217A (pt) |
| WO (1) | WO2011002285A1 (pt) |
Families Citing this family (54)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US9040468B2 (en) | 2007-07-25 | 2015-05-26 | Schlumberger Technology Corporation | Hydrolyzable particle compositions, treatment fluids and methods |
| US10011763B2 (en) | 2007-07-25 | 2018-07-03 | Schlumberger Technology Corporation | Methods to deliver fluids on a well site with variable solids concentration from solid slurries |
| US20160257872A9 (en) * | 2010-09-17 | 2016-09-08 | Schlumberger Technology Corporation | Solid state dispersion |
| GB2487712B (en) | 2011-01-04 | 2015-10-28 | Otsuka Pharma Co Ltd | Use of the phytocannabinoid cannabidiol (CBD) in combination with a standard anti-epileptic drug (SAED) in the treatment of epilepsy |
| GB2495118B (en) | 2011-09-29 | 2016-05-18 | Otsuka Pharma Co Ltd | A pharmaceutical composition comprising the phytocannabinoids cannabidivarin (CBDV) and cannabidiol (CBD) |
| WO2013063580A1 (en) * | 2011-10-28 | 2013-05-02 | Baxter International Inc. | Nonaqueous compositions for bone hemostasis, and methods for their use and manufacture |
| CN103897181B (zh) * | 2012-12-27 | 2017-02-08 | 张昊 | 聚合物、其制备方法和应用 |
| JP6232262B2 (ja) * | 2013-11-13 | 2017-11-15 | アクアス株式会社 | 徐放性を有する固形水処理剤、およびその製造方法 |
| US11033493B2 (en) | 2013-12-02 | 2021-06-15 | Intelgenx Corp. | Film dosage form with extended release mucoadhesive particles |
| US10206880B2 (en) | 2014-04-17 | 2019-02-19 | Sandoz Ag | Solid dispersion comprising an orexin receptor antagonist |
| GB2530001B (en) | 2014-06-17 | 2019-01-16 | Gw Pharma Ltd | Use of cannabidiol in the reduction of convulsive seizure frequency in treatment-resistant epilepsy |
| GB2531281A (en) | 2014-10-14 | 2016-04-20 | Gw Pharma Ltd | Use of cannabidiol in the treatment of intractable epilepsy |
| GB2531278A (en) | 2014-10-14 | 2016-04-20 | Gw Pharma Ltd | Use of cannabidiol in the treatment of intractable epilepsy |
| GB2531282A (en) | 2014-10-14 | 2016-04-20 | Gw Pharma Ltd | Use of cannabinoids in the treatment of epilepsy |
| US10834922B2 (en) | 2014-11-26 | 2020-11-17 | Microban Products Company | Surface disinfectant with residual biocidal property |
| US10925281B2 (en) | 2014-11-26 | 2021-02-23 | Microban Products Company | Surface disinfectant with residual biocidal property |
| US10842147B2 (en) | 2014-11-26 | 2020-11-24 | Microban Products Company | Surface disinfectant with residual biocidal property |
| US11033023B2 (en) | 2014-11-26 | 2021-06-15 | Microban Products Company | Surface disinfectant with residual biocidal property |
| GB2539472A (en) | 2015-06-17 | 2016-12-21 | Gw Res Ltd | Use of cannabinoids in the treatment of epilepsy |
| GB2541191A (en) | 2015-08-10 | 2017-02-15 | Gw Pharma Ltd | Use of cannabinoids in the treatment of epilepsy |
| AU2016326626A1 (en) * | 2015-09-24 | 2018-04-26 | Pasenture, Inc. | Cannabinoid compositions and methods of making |
| EP3379932A4 (en) * | 2015-11-23 | 2019-05-01 | Microban Products Company | SURFACE DISINFECTANT WITH REMAINING BIOCIDAL PROPERTIES |
| MX2018006394A (es) * | 2015-11-23 | 2019-02-14 | Microban Products | Desinfectante de superficie con propiedad biocida residual. |
| GB2548873B (en) | 2016-03-31 | 2020-12-02 | Gw Res Ltd | Use of Cannabidiol in the Treatment of SturgeWeber Syndrome |
| US9913871B2 (en) | 2016-04-15 | 2018-03-13 | Fairhaven Health, Llc | Compositions and methods for maintaining or enhancing homeostasis or function of female lower reproductive tract |
| US11503824B2 (en) | 2016-05-23 | 2022-11-22 | Microban Products Company | Touch screen cleaning and protectant composition |
| GB2551987A (en) | 2016-07-01 | 2018-01-10 | Gw Res Ltd | Oral cannabinoid formulations |
| GB2551986A (en) | 2016-07-01 | 2018-01-10 | Gw Res Ltd | Parenteral formulations |
| GB2551985B (en) * | 2016-07-01 | 2019-01-30 | Gw Res Ltd | Novel formulation |
| GB2553139A (en) | 2016-08-25 | 2018-02-28 | Gw Res Ltd | Use of cannabinoids in the treatment of multiple myeloma |
| GB2557921A (en) | 2016-12-16 | 2018-07-04 | Gw Res Ltd | Use of cannabinoids in the treatment of angelman syndrome |
| GB2559774B (en) | 2017-02-17 | 2021-09-29 | Gw Res Ltd | Oral cannabinoid formulations |
| GB2560019A (en) | 2017-02-27 | 2018-08-29 | Gw Res Ltd | Use of cannabinoids in the treatment of leukaemia |
| GB2564383B (en) | 2017-06-23 | 2021-04-21 | Gw Res Ltd | Use of cannabidiol in the treatment of tumours assoicated with Tuberous Sclerosis Complex |
| GB2568929A (en) | 2017-12-01 | 2019-06-05 | Gw Res Ltd | Use of cannabinoids in the treatment of epilepsy |
| GB2569961B (en) * | 2018-01-03 | 2021-12-22 | Gw Res Ltd | Pharmaceutical |
| GB2572126B (en) * | 2018-01-03 | 2021-01-13 | Gw Res Ltd | Pharmaceutical |
| GB2572125B (en) * | 2018-01-03 | 2021-01-13 | Gw Res Ltd | Pharmaceutical |
| US11793878B2 (en) * | 2018-03-16 | 2023-10-24 | Universiteit Gent | Drug formulations comprising polyoxazolines as matrix excipient |
| AU2019260810A1 (en) * | 2018-04-27 | 2020-11-19 | Remy Biosciences, Inc. | New medical devices, delivery vehicles and manufacturing thereof |
| CA3098423A1 (en) * | 2018-05-04 | 2019-11-07 | Fenelon Holland Holding B.V. | Visualizing agent for visualizing hyaluronan |
| US10828254B2 (en) | 2018-09-28 | 2020-11-10 | Intelgenx Corp. | Oral film formulation for modulating absorption profile |
| US11602504B2 (en) | 2018-11-05 | 2023-03-14 | Intelgenx Corp. | Lipophilic active oral film formulation and method of making the same |
| US12303501B2 (en) | 2018-11-05 | 2025-05-20 | Intelgenx Corp. | Lipophilic active oral film formulation and method of making the same |
| GB202002754D0 (en) | 2020-02-27 | 2020-04-15 | Gw Res Ltd | Methods of treating tuberous sclerosis complex with cannabidiol and everolimus |
| US11160757B1 (en) | 2020-10-12 | 2021-11-02 | GW Research Limited | pH dependent release coated microparticle cannabinoid formulations |
| WO2022103638A1 (en) * | 2020-11-16 | 2022-05-19 | Orcosa Inc. | Cannabinoids in the treatment of autism spectrum disorder |
| WO2022232574A1 (en) | 2021-04-29 | 2022-11-03 | Tilray, Inc. | Cannabidiol-dominant formulations, methods of manufacturing, and uses thereof |
| WO2024033521A1 (en) | 2022-08-12 | 2024-02-15 | GW Research Limited | Oral solid dosage forms comprising cannabinoids |
| JP7469550B1 (ja) * | 2022-10-21 | 2024-04-16 | 第一工業製薬株式会社 | 固体組成物及びその製造方法 |
| KR102945684B1 (ko) * | 2023-02-14 | 2026-03-30 | 주식회사 티앤알바이오팹 | 조직재생 촉진형 약물전달 조성물 및 이를 포함하는 약물 전달용 키트 |
| WO2026015019A1 (en) | 2024-07-08 | 2026-01-15 | InnoCore Technologies Holding B.V. | Biodegradable thermoplastic polyoxazoline based copolymers |
| WO2026013080A1 (en) | 2024-07-08 | 2026-01-15 | InnoCore Technologies Holding B.V. | Pharmaceutical composition based on biodegradable polymers comprising polyoxazoline |
| US12605394B2 (en) | 2024-07-25 | 2026-04-21 | Visionary Assets, Llc | Compositions containing cannabinoid nanoparticles |
Family Cites Families (13)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US4990339A (en) | 1987-11-16 | 1991-02-05 | H. B. Fuller Company | Dermal treatment film |
| US5536505A (en) | 1993-12-15 | 1996-07-16 | Eastman Chemical Company | Controlled release matrix system using cellulose acetate/poly-2-ethyl-2-oxazoline blends |
| DE19753299A1 (de) | 1997-12-01 | 1999-06-02 | Basf Ag | Verfahren zur Herstellung von festen Dosierungsformen |
| US6372254B1 (en) | 1998-04-02 | 2002-04-16 | Impax Pharmaceuticals Inc. | Press coated, pulsatile drug delivery system suitable for oral administration |
| US6716450B1 (en) | 2000-05-18 | 2004-04-06 | The United States Of America As Represented By The Secretary Of The Army | Enhancing protein activity through nanoencapsulation |
| AU2001296909A1 (en) | 2000-09-28 | 2002-04-08 | Ganado Research, L.L.C. | Pain relief implant pellet and method using same |
| DK1361864T3 (en) | 2001-02-14 | 2014-03-03 | Gw Pharma Ltd | FLYLDENDE SPRAY FORMULATIONS FOR buccal administration of cannabinoids |
| AU2003240824B9 (en) | 2002-05-31 | 2008-09-25 | University Of Mississippi | Transmucosal delivery of cannabinoids |
| ITMI20022748A1 (it) | 2002-12-23 | 2004-06-24 | Eurand Int | Dispersioni solide stabilizzate di farmaco in un carrier organico e procedimento per la loro preparazione. |
| TWI366460B (en) * | 2005-06-16 | 2012-06-21 | Euro Celtique Sa | Cannabinoid active pharmaceutical ingredient for improved dosage forms |
| US20070183987A1 (en) | 2006-02-08 | 2007-08-09 | Jensen Steven D | Peroxide Gel Compositions |
| US20080026040A1 (en) * | 2006-07-31 | 2008-01-31 | Isaac Farr | Active agent-releasing dosage forms |
| JP5671457B2 (ja) | 2008-06-26 | 2015-02-18 | テクニシェ ユニバーシタット ミュンヘン | 活性剤のためのポリマーデリバリーシステム |
-
2010
- 2010-06-28 BR BRPI1014139A patent/BRPI1014139A2/pt active Search and Examination
- 2010-06-28 EP EP10728431A patent/EP2448567B1/en active Active
- 2010-06-28 MX MX2012000217A patent/MX2012000217A/es active IP Right Grant
- 2010-06-28 CN CN201080034203.2A patent/CN102481264B/zh not_active Expired - Fee Related
- 2010-06-28 JP JP2012517430A patent/JP5666574B2/ja not_active Expired - Fee Related
- 2010-06-28 ES ES10728431T patent/ES2409055T3/es active Active
- 2010-06-28 CA CA2766482A patent/CA2766482C/en not_active Expired - Fee Related
- 2010-06-28 KR KR1020127002346A patent/KR101701544B1/ko not_active Expired - Fee Related
- 2010-06-28 WO PCT/NL2010/050403 patent/WO2011002285A1/en not_active Ceased
- 2010-06-28 US US13/381,271 patent/US8642080B2/en not_active Expired - Fee Related
Also Published As
| Publication number | Publication date |
|---|---|
| WO2011002285A1 (en) | 2011-01-06 |
| US20120183606A1 (en) | 2012-07-19 |
| JP5666574B2 (ja) | 2015-02-12 |
| AU2010266846A1 (en) | 2012-02-09 |
| AU2010266846A2 (en) | 2012-02-09 |
| EP2448567B1 (en) | 2013-03-13 |
| US8642080B2 (en) | 2014-02-04 |
| MX2012000217A (es) | 2012-05-08 |
| CN102481264A (zh) | 2012-05-30 |
| AU2010266846A8 (en) | 2016-01-07 |
| ES2409055T3 (es) | 2013-06-24 |
| CN102481264B (zh) | 2015-04-22 |
| CA2766482C (en) | 2017-10-24 |
| KR101701544B1 (ko) | 2017-02-01 |
| EP2448567A1 (en) | 2012-05-09 |
| AU2010266846B2 (en) | 2016-02-04 |
| KR20120107064A (ko) | 2012-09-28 |
| JP2012532099A (ja) | 2012-12-13 |
| CA2766482A1 (en) | 2011-01-06 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| BRPI1014139A2 (pt) | sistema de liberação de fármacos compreendendo polioxazolina e um agente biotivo. | |
| BRPI1013399A2 (pt) | sistema de entrega de fármaco intervencional e métodos associados | |
| BRPI0917030A2 (pt) | sistema de liberação de fármaco contendo progestina | |
| BR112012000786A2 (pt) | conjunto de mancal de impulso, sistema de direção, e dispositivo de envio de medicamento | |
| BRPI0913214A2 (pt) | sistema de fornecimento de drogas transdérmico estabilizado | |
| BR112012002981A2 (pt) | sistema de liberação de fármaco oftálmico contendo fosfolipídio e colesterol. | |
| BR112013012818A2 (pt) | módulo medicamentoso e sistema de administração de fármaco | |
| EP3323405C0 (en) | SYSTEM AND METHOD FOR DISPENSING MEDICATION | |
| BRPI1015947A2 (pt) | dispositivos para distribuição de fármacos e sistemas e métodos relacionados | |
| BRPI0716196A2 (pt) | Sistemas de distribuição de fármacos que compreendem soluções sólidas de fármacos fracamente básicos. | |
| BRPI1014975A2 (pt) | sistema de entrega de implante | |
| BRPI0818129A2 (pt) | Sistema de transporte e administração de medicamento seguro | |
| IL243709A0 (en) | Devices, systems and methods for medicament delivery | |
| BRPI0920690A2 (pt) | sistema de distribuição de stent restringível | |
| BRPI0917358A2 (pt) | formulação farmacêutica de liberação controlada e método. | |
| BRPI1010279A2 (pt) | dispositivo de distribuição de fármaco | |
| DK2398500T3 (da) | Glutathion-baseret lægemiddelafgivelsessystem | |
| BRPI0821876A8 (pt) | sistemas e métodos para administração de medicação | |
| BRPI1007457A2 (pt) | Conjungado, formulação de liberação prolongada, e, sistema de distribuição de bomba. | |
| BRPI1007466A2 (pt) | conjugado de insulina cristalina, formulação de liberação prolongada, e, sistema de distribuição de bomba | |
| BRPI1012730A2 (pt) | dispositivo de distribuição de fármaco | |
| DK3756657T3 (da) | Synkbar anordning til lægemiddelfremføring | |
| DK2493532T3 (da) | Lægemiddelfremføringsanordning | |
| DK2296732T3 (da) | Medikamentafgivelsesindretning | |
| BRPI0814759A2 (pt) | Sistema de administração e notificação de medicamento específico de paciente |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| B07D | Technical examination (opinion) related to article 229 of industrial property law [chapter 7.4 patent gazette] | ||
| B06F | Objections, documents and/or translations needed after an examination request according [chapter 6.6 patent gazette] | ||
| B07E | Notification of approval relating to section 229 industrial property law [chapter 7.5 patent gazette] |
Free format text: NOTIFICACAO DE ANUENCIA RELACIONADA COM O ART 229 DA LPI |
|
| B06U | Preliminary requirement: requests with searches performed by other patent offices: procedure suspended [chapter 6.21 patent gazette] | ||
| B09A | Decision: intention to grant [chapter 9.1 patent gazette] | ||
| B11D | Dismissal acc. art. 38, par 2 of ipl - failure to pay fee after grant in time |